-Advertisement-
-Advertisement-
Glaucoma
FDA accepts premarket approval application for DE-128 microshunt
Posted on
The U.S. Food and Drug Administration has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review, according to a press release from Santen Pharmaceutical Co.
The microshunt is an investigational surgical glaucoma implant designed to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) whose IOP is not controlled when using maximum tolerated glaucoma medications.
Read the full press release here.
Source: Santen Pharmaceutical Co., Ltd.
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved